mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
复制标题
DOI：
10.3390/v14020401
复制
发表时间：
2022-02-15
期刊：
影响因子：
--
通讯作者：
Yin X
中科院分区：
文献类型：
--
作者：
Le T;Sun C;Chang J;Zhang G;Yin X
在传染病的预防和治疗方面，mRNA疫苗具有插入突变风险低、效价高、开发周期快和低成本生产的潜力，因此在传染病的预防和治疗方面具有很大的前景。在过去的几年里，几种RNA疫苗已经进入临床试验，并显示出为抗击狂犬病、寨卡病毒和流感等新出现和再次出现的传染病提供解决方案的前景。最近，针对新冠肺炎的基因疫苗的成功应用进一步验证了这一平台，并为基因疫苗在传染病预防，特别是在兽医领域的潜力打开了闸门。在这篇综述中，我们描述了我们目前对信使核糖核酸疫苗的理解以及用于信使核糖核酸疫苗开发的技术。我们还概述了针对动物传染病开发的mRNA疫苗，并讨论了这一前景广阔的疫苗平台在兽医领域未来应用的方向和挑战。
In the prevention and treatment of infectious diseases, mRNA vaccines hold great promise because of their low risk of insertional mutagenesis, high potency, accelerated development cycles, and potential for low-cost manufacture. In past years, several mRNA vaccines have entered clinical trials and have shown promise for offering solutions to combat emerging and re-emerging infectious diseases such as rabies, Zika, and influenza. Recently, the successful application of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine’s potential in infectious disease prevention, especially in the veterinary field. In this review, we describe our current understanding of the mRNA vaccines and the technologies used for mRNA vaccine development. We also provide an overview of mRNA vaccines developed for animal infectious diseases and discuss directions and challenges for the future applications of this promising vaccine platform in the veterinary field.
登录
查看更多内容
影响因子：
32.4
作者：
Alameh MG;Tombácz I;Bettini E;Lederer K;Sittplangkoon C;Wilmore JR;Gaudette BT;Soliman OY;Pine M;Hicks P;Manzoni TB;Knox JJ;Johnson JL;Laczkó D;Muramatsu H;Davis B;Meng W;Rosenfeld AM;Strohmeier S;Lin PJC;Mui BL;Tam YK;Karikó K;Jacquet A;Krammer F;Bates P;Cancro MP;Weissman D;Luning Prak ET;Allman D;Locci M;Pardi N
通讯作者：
Pardi N
影响因子：
14.9
作者：
Abou Assi H;Rangadurai AK;Shi H;Liu B;Clay MC;Erharter K;Kreutz C;Holley CL;Al-Hashimi HM
通讯作者：
Al-Hashimi HM
影响因子：
7.8
作者：
Buschmann MD;Carrasco MJ;Alishetty S;Paige M;Alameh MG;Weissman D
通讯作者：
Weissman D
影响因子：
5.4
作者：
Aberle, JH;Aberle, SW;Mandl, CW
通讯作者：
Mandl, CW
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group